Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Young
John J
JJ
The Lindner Center for Research and Education, The Ohio Heart and Vascular Center, 2123 Auburn Avenue, Suite 136, Cincinnati, OH, 45219, USA. youngj@ohioheart.org
D000077284:Abciximab; D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000628:therapy; D010455:Peptides / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab